Standard BioTools Inc. filings document the regulatory record for a life-science research tools company centered on mass cytometry, microfluidics, genomics, single-cell proteomics and spatial proteomics. Current reports cover operating results, revenue outlook disclosures, restructuring and cost-savings actions, capital-structure changes, material agreements and risk factors tied to its research-use instrument, consumable and service portfolio.
Proxy materials describe board elections, executive compensation votes, auditor ratification, equity incentive plan approvals and employee stock purchase plan amendments. Form 8-K filings also record material events such as the completed SomaLogic sale, related financial disclosures, shareholder voting matters and Nasdaq continued-listing compliance notices.
Standard BioTools Inc. plans an all-stock merger with Treeline Biosciences, Inc., valuing Treeline at $2.5 billion and Standard BioTools at $460 million, subject to Parent Net Cash adjustments. Treeline holders are currently estimated to receive about 11.6997 LAB shares per Treeline share, with former Treeline and Standard BioTools stockholders expected to own roughly 84% and 16% of the combined company on a fully diluted basis.
At closing, the company will be renamed Treeline Biosciences Holdings, Inc. and effect a reverse stock split, and expects its stock to trade on Nasdaq as “TRLN”. Each existing LAB share is expected to receive one contingent value right (CVR), collectively allowing issuance of up to 76,000,000 shares over five years from monetizing the mass cytometry and microfluidics “Legacy Business,” certain investments and earnouts, and any surplus Parent Net Cash. Standard BioTools must pursue sale or wind-down of the Legacy Business.
The S-4 also covers resale of shares received by Treeline stockholders; Standard BioTools will not receive proceeds from these resales. A $16.1 million termination fee and up to $5 million expense reimbursement may be payable in specified break scenarios. Voting agreements cover about 39% of LAB shares, and major Treeline holders and directors are subject to 180‑day lock‑ups.
STANDARD BIOTOOLS INC. director Carey Thomas D. reported equity compensation grants consisting of restricted stock units and stock options. He received 99,116 RSUs that vest in full on the earlier of June 18, 2027 or one day before the next annual stockholders’ meeting, subject to continued service. Each RSU converts into one share of common stock at vesting. He was also granted stock options for 263,884 shares at an exercise price of $0.8297 per share, vesting in twelve equal monthly installments beginning on July 18, 2026, and expiring on June 18, 2036. Following these awards, he directly holds 344,456 shares of common stock and 263,884 stock options.
Mackay Sean reported acquisition or exercise transactions in this Form 4 filing.
STANDARD BIOTOOLS INC. reported that SVP & Chief Business Officer Sean Mackay received a grant of 500,000 shares of Common Stock in the form of restricted stock units. These RSUs were granted at no cash cost and increase his direct holdings to 1,506,552 shares after the award.
The RSUs vest over time based on continued service: 40% will vest on June 20, 2027 and the remaining 60% will vest on June 20, 2028, so Mackay receives the underlying shares only if he remains with the company through those dates.
STANDARD BIOTOOLS INC. director Frank Witney reported new equity awards that increase his stake in the company. On June 18, 2026, he received 99,116 Restricted Stock Units (RSUs) and a stock option for 175,923 shares with an exercise price of $0.8297 per share.
The RSUs vest in full on the earlier of June 18, 2027 or one day before the next annual stockholder meeting, subject to continued service. The option vests in twelve equal monthly installments beginning July 18, 2026 and expires on June 18, 2036. Following these grants, Witney holds 309,978 common shares directly and 4,225 shares indirectly through a revocable trust, in addition to the new option position.
STANDARD BIOTOOLS INC. director and 10% owner Eli Casdin reported new equity awards and updated holdings in Form 4. He received 99,116 Restricted Stock Units that vest in full on the earlier of June 18, 2027 and one day before the company’s next annual stockholder meeting, with each RSU delivering one share of common stock upon vesting.
Casdin was also granted stock options for 175,923 shares of common stock at an exercise price of $0.8297 per share, expiring on June 18, 2036 and becoming exercisable in twelve equal monthly installments starting July 18, 2026. Following these awards, he holds 3,053,169 shares directly and has additional indirect holdings of 72,100,000 shares through Casdin Partners Master Fund, L.P., 2,744,219 shares through Casdin Private Growth Equity Fund, L.P., and 13,939,637 shares through Casdin Private Growth Equity Fund II, L.P.
STANDARD BIOTOOLS INC. director Troy Cox reported equity awards consisting of restricted stock units and stock options as part of his compensation. He received 99,116 RSUs that vest in full on the earlier of June 18, 2027, or one day before the company’s next annual stockholder meeting, subject to continued service. He also received stock options covering 175,923 shares of common stock at an exercise price of $0.8297 per share, vesting in twelve equal monthly installments beginning July 18, 2026, and expiring on June 18, 2036. Following these awards, he directly holds 475,702 shares of common stock.
STANDARD BIOTOOLS INC. director Eloi Fenel M reported equity awards consisting of restricted stock units and stock options. He received 99,116 RSUs that vest in full on the earlier of June 18, 2027 or one day before the next annual stockholders’ meeting, contingent on continued service. Each RSU converts into one common share at vesting, bringing direct common stock holdings to 335,299 shares after the award. He was also granted a stock option for 175,923 shares at an exercise price of $0.8297 per share, vesting in twelve equal monthly installments beginning July 18, 2026 and expiring on June 18, 2036.
STANDARD BIOTOOLS INC. director Kathy L. Hibbs reported equity awards that increase her stake in the company. On June 18, 2026, she received 99,116 shares of Common Stock as Restricted Stock Units that vest in full on the earlier of June 18, 2027 and one day prior to the next annual stockholders’ meeting, subject to continued service.
She also received a stock option for 175,923 shares of Common Stock at an exercise price of $0.8297 per share, becoming exercisable in twelve equal monthly installments beginning on July 18, 2026, also subject to continued service. After these awards, she directly owns 236,836 shares plus 175,923 stock options.
Standard BioTools Inc. held its 2026 Annual Meeting of Stockholders on June 17, 2026. Stockholders approved the company’s new 2026 Equity Incentive Plan and an amendment to the Amended and Restated 2017 Employee Stock Purchase Plan, increasing the shares of common stock reserved under the ESPP by 1,200,000 shares.
Three Class I directors were elected to serve until the 2029 annual meeting, and stockholders gave advisory approval to executive compensation for 2025. They also ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for 2026. On the April 24, 2026 record date, the company had 390,368,119 shares of common stock outstanding, and approximately 86.04% of voting power was represented at the meeting.
Viking Global Investors and affiliates filed a Schedule 13D reporting beneficial ownership of 58,651,170 shares of Standard BioTools common stock, or about 15% of the company. This stake is held through VGOP with 39,296,310 shares and VGOD with 19,354,860 shares, based on 390,368,119 shares outstanding as of May 4, 2026.
The filing follows conversion of all Series B-2 preferred stock into common stock. Viking has entered into a Voting Agreement to support Standard BioTools’ proposed merger with Treeline Biosciences, related share issuance, a corporate name change to Treeline Biosciences Holdings, Inc., a reverse stock split, and new post-closing equity plans. The agreement caps covered shares at 58,651,170 and restricts dispositions, and Viking notes a Rule 13d-1(e)(2) cooling-off period ending ten days after this filing.